{"id":1777,"date":"2026-03-25T13:35:08","date_gmt":"2026-03-25T17:35:08","guid":{"rendered":"https:\/\/www.provem.ca\/trajectoires-therapeutiques-en-cancers-urologiques\/"},"modified":"2026-04-01T06:34:26","modified_gmt":"2026-04-01T10:34:26","slug":"trajectoires-therapeutiques-en-cancers-urologiques","status":"publish","type":"post","link":"https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/","title":{"rendered":"Trajectoires th\u00e9rapeutiques en cancers urologiques"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\"><strong>\u00c9valuation longitudinale du paysage th\u00e9rapeutique, de la toxicit\u00e9 et du profilage mol\u00e9culaire des cancers urologiques : une d\u00e9cennie de donn\u00e9es probantes en vie r\u00e9elle<\/strong><\/h3>\n\n<p><strong>Chercheuse principale :<\/strong> Dre Alice Dragomir<br\/><strong>Institution :<\/strong> McGill University Health Centre (MUHC)<br\/><strong>Sponsor : <\/strong>PROVEM<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>Contexte scientifique<\/strong><\/h3>\n\n<p>Les cancers urologiques, notamment les cancers de la prostate, de la vessie et du rein, repr\u00e9sentent une part importante du fardeau oncologique au Canada. Au cours de la derni\u00e8re d\u00e9cennie, leur prise ne charge a profond\u00e9ment \u00e9volu\u00e9 avec l\u2019introduction de nouvelles classes th\u00e9rapeutiques telles que les inhibiteurs du r\u00e9cepteur aux androg\u00e8nes, les inhibiteurs de PARP, les immunoth\u00e9rapies, les th\u00e9rapies cibl\u00e9es et les radio-ligands. <\/p>\n\n<p>Parall\u00e8lement, le d\u00e9veloppement du profilage mol\u00e9culaire et l\u2019\u00e9largissement des panels diagnostiques ont transform\u00e9 les strat\u00e9gies th\u00e9rapeutiques en oncologie de pr\u00e9cision. Ces innovations ont consid\u00e9rablement augment\u00e9 les options th\u00e9rapeutiques, mais ont \u00e9galement complexifi\u00e9 les trajectoires de soins et les d\u00e9cisions cliniques concernant la s\u00e9quence optimale des traitements. <\/p>\n\n<p>Avec cette \u00e9volution rapide, la compr\u00e9hension des s\u00e9quences th\u00e9rapeutiques optimales, de l\u2019utilisation r\u00e9elle des innovations et de leur impact sur les r\u00e9sultats cliniques demeure limit\u00e9e en pratique r\u00e9elle.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>Objectifs<\/strong><\/h3>\n\n<p>Ce projet vise \u00e0 caract\u00e9riser de mani\u00e8re int\u00e9gr\u00e9e les trajectoires th\u00e9rapeutiques en oncologie urologique en conditions r\u00e9elles, afin de mieux comprendre l\u2019utilisation et l\u2019impact des innovations cliniques au cours de la derni\u00e8re d\u00e9cennie afin de :<\/p>\n\n<ul class=\"wp-block-list\">\n<li>D\u00e9crire l\u2019\u00e9volution des sch\u00e9mas th\u00e9rapeutiques en oncologie urologique<\/li>\n\n\n\n<li>\u00c9valuer l\u2019impact r\u00e9el des nouvelles th\u00e9rapies sur les r\u00e9sultats cliniques des patients<\/li>\n\n\n\n<li>Examiner les dynamiques d\u2019adoption des innovations th\u00e9rapeutiques et les transitions entre lignes de traitement<\/li>\n\n\n\n<li>Analyser l\u2019influence des tests mol\u00e9culaires et du profilage g\u00e9nomique sur l\u2019utilisation des th\u00e9rapies cibl\u00e9es<\/li>\n\n\n\n<li>Identifier les variations dans l\u2019adoption des innovations et leurs associations avec les r\u00e9sultats cliniques et l\u2019utilisation des ressources de sant\u00e9.<\/li>\n<\/ul>\n\n<h3 class=\"wp-block-heading\"><strong>Population et donn\u00e9es mobilis\u00e9es<\/strong><\/h3>\n\n<ul class=\"wp-block-list\">\n<li>Population :<br\/>Patients adultes ayant re\u00e7u un diagnostic de cancer urologique (prostate, vessie ou rein) entre le 1er janvier 2015 et le 1er janvier 2025 au MUHC.<br\/>Les patients seront suivis longitudinalement depuis la date de diagnostic jusqu\u2019au 31 juillet 2025.<\/li>\n\n\n\n<li>Donn\u00e9es :<br>Le projet mobilise des donn\u00e9es cliniques riches issues du MUHC Data Warehouse, incluant notamment :\n<ul class=\"wp-block-list\">\n<li>Donn\u00e9es d\u00e9mographiques et caract\u00e9ristiques cliniques<\/li>\n\n\n\n<li><span style=\"color: initial;\">Diagnostics et stades tumoraux<\/span><\/li>\n\n\n\n<li><span style=\"color: initial;\">Interventions chirurgicales<\/span><\/li>\n\n\n\n<li><span style=\"color: initial;\">Traitements syst\u00e9miques et radioth\u00e9rapie<\/span><\/li>\n\n\n\n<li><span style=\"color: initial;\">R\u00e9sultats de laboratoire (incluant pathologie mol\u00e9culaire)<\/span><\/li>\n\n\n\n<li><span style=\"color: initial;\">Prescriptions pharmaceutiques<\/span><\/li>\n\n\n\n<li>Hospitalisations et visites aux urgences<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n<p>La richesse et la granularit\u00e9 de ces donn\u00e9es cliniques permettent une analyse d\u00e9taill\u00e9e des trajectoires de soins et des d\u00e9cisions th\u00e9rapeutiques en contexte r\u00e9el.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>Approche m\u00e9thodologique<\/strong><\/h3>\n\n<p>L\u2019\u00e9tude repose sur un design de cohorte r\u00e9trospective longitudinale utilisant des donn\u00e9es cliniques en vie r\u00e9elle issues du data Warehouse hospitalier.<\/p>\n\n<p>Les principales approches analytiques incluent :<\/p>\n\n<ul class=\"wp-block-list\">\n<li>Analyses descriptives des caract\u00e9ristiques des patients et des sch\u00e9mas th\u00e9rapeutiques<\/li>\n\n\n\n<li>Analyses de survie (Kaplan-Meier et mod\u00e8les de Cox)<\/li>\n\n\n\n<li>Analyses de s\u00e9quences th\u00e9rapeutiques et visualisation des trajectoires<\/li>\n<\/ul>\n\n<p>Cette approche permet de reconstruire les s\u00e9quences th\u00e9rapeutiques complexes et d\u2019identifier des sch\u00e9mas d\u2019utilisation des traitements en conditions r\u00e9elles, en lien avec les r\u00e9sultats cliniques et l\u2019utilisation des ressources.<\/p>\n\n<p>Ce projet apporte une analyse clinique approfondie des trajectoires de soins et de l\u2019adoption des innovations, en compl\u00e9ment des approches populationnelles et multi-sources d\u00e9velopp\u00e9es au sein de PROVEM.<\/p>\n\n<h3 class=\"wp-block-heading\"><strong>Statut du projet<\/strong><\/h3>\n\n<p>Phase actuelle protocole soumis au comit\u00e9 d\u2019\u00e9thique et pr\u00e9paration des \u00e9tapes d\u2019extraction et d\u2019analyse des donn\u00e9es.<br\/>Prochaine \u00e9tape :<\/p>\n\n<ul class=\"wp-block-list\">\n<li>L\u2019approbation \u00e9thique<\/li>\n\n\n\n<li>Extraction des donn\u00e9es du MUHC Data Warehouse<\/li>\n\n\n\n<li>D\u00e9but des analyses.<\/li>\n<\/ul>\n\n<h3 class=\"wp-block-heading\"><strong>Signature institutionnelle<\/strong><\/h3>\n\n<p>PROVEM est une plateforme d\u00e9di\u00e9e \u00e0 la mobilisation et \u00e0 l\u2019analyse de donn\u00e9es de vie r\u00e9elle en oncologie au Qu\u00e9bec, int\u00e9grant des donn\u00e9es cliniques, administratives et rapport\u00e9es par les patients afin de produire des analyses multi-\u00e9chelles pour \u00e9clairer la prise de d\u00e9cision.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00c9valuation longitudinale du paysage th\u00e9rapeutique, de la toxicit\u00e9 et du profilage mol\u00e9culaire des cancers urologiques : une d\u00e9cennie de donn\u00e9es probantes en vie r\u00e9elle Chercheuse principale : Dre Alice DragomirInstitution : McGill University Health Centre (MUHC)Sponsor : PROVEM Contexte scientifique Les cancers urologiques, notamment les cancers de la prostate, de la vessie et du rein, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1776,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"type-post":[58],"communication-type":[64],"data-type":[74],"usage":[84,87],"class_list":["post-1777","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","type-post-projet","communication-type-lancement","data-type-donnees-cliniques","usage-resultats-cliniques","usage-sequence-dadministration"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Trajectoires th\u00e9rapeutiques en cancers urologiques - Provem<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trajectoires th\u00e9rapeutiques en cancers urologiques - Provem\" \/>\n<meta property=\"og:description\" content=\"\u00c9valuation longitudinale du paysage th\u00e9rapeutique, de la toxicit\u00e9 et du profilage mol\u00e9culaire des cancers urologiques : une d\u00e9cennie de donn\u00e9es probantes en vie r\u00e9elle Chercheuse principale : Dre Alice DragomirInstitution : McGill University Health Centre (MUHC)Sponsor : PROVEM Contexte scientifique Les cancers urologiques, notamment les cancers de la prostate, de la vessie et du rein, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/\" \/>\n<meta property=\"og:site_name\" content=\"Provem\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-25T17:35:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T10:34:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.provem.ca\/wp-content\/uploads\/2026\/03\/doctor-and-patient-sitting-and-talking-at-medical-2026-03-16-23-01-30-utc.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1697\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"adminProvem_beta\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminProvem_beta\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.provem.ca\\\/fr\\\/trajectoires-therapeutiques-en-cancers-urologiques\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.provem.ca\\\/fr\\\/trajectoires-therapeutiques-en-cancers-urologiques\\\/\"},\"author\":{\"name\":\"adminProvem_beta\",\"@id\":\"https:\\\/\\\/www.provem.ca\\\/#\\\/schema\\\/person\\\/61bc22381a98ee7dc1d4468e7cae5e01\"},\"headline\":\"Trajectoires th\u00e9rapeutiques en cancers urologiques\",\"datePublished\":\"2026-03-25T17:35:08+00:00\",\"dateModified\":\"2026-04-01T10:34:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.provem.ca\\\/fr\\\/trajectoires-therapeutiques-en-cancers-urologiques\\\/\"},\"wordCount\":702,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.provem.ca\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.provem.ca\\\/fr\\\/trajectoires-therapeutiques-en-cancers-urologiques\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.provem.ca\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/doctor-and-patient-sitting-and-talking-at-medical-2026-03-16-23-01-30-utc.webp\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.provem.ca\\\/fr\\\/trajectoires-therapeutiques-en-cancers-urologiques\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.provem.ca\\\/fr\\\/trajectoires-therapeutiques-en-cancers-urologiques\\\/\",\"url\":\"https:\\\/\\\/www.provem.ca\\\/fr\\\/trajectoires-therapeutiques-en-cancers-urologiques\\\/\",\"name\":\"Trajectoires th\u00e9rapeutiques en cancers urologiques - Provem\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.provem.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.provem.ca\\\/fr\\\/trajectoires-therapeutiques-en-cancers-urologiques\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.provem.ca\\\/fr\\\/trajectoires-therapeutiques-en-cancers-urologiques\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.provem.ca\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/doctor-and-patient-sitting-and-talking-at-medical-2026-03-16-23-01-30-utc.webp\",\"datePublished\":\"2026-03-25T17:35:08+00:00\",\"dateModified\":\"2026-04-01T10:34:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.provem.ca\\\/fr\\\/trajectoires-therapeutiques-en-cancers-urologiques\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.provem.ca\\\/fr\\\/trajectoires-therapeutiques-en-cancers-urologiques\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.provem.ca\\\/fr\\\/trajectoires-therapeutiques-en-cancers-urologiques\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.provem.ca\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/doctor-and-patient-sitting-and-talking-at-medical-2026-03-16-23-01-30-utc.webp\",\"contentUrl\":\"https:\\\/\\\/www.provem.ca\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/doctor-and-patient-sitting-and-talking-at-medical-2026-03-16-23-01-30-utc.webp\",\"width\":1697,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.provem.ca\\\/fr\\\/trajectoires-therapeutiques-en-cancers-urologiques\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.provem.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trajectoires th\u00e9rapeutiques en cancers urologiques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.provem.ca\\\/#website\",\"url\":\"https:\\\/\\\/www.provem.ca\\\/\",\"name\":\"Provem\",\"description\":\"Provem website\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.provem.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.provem.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.provem.ca\\\/#organization\",\"name\":\"Provem\",\"url\":\"https:\\\/\\\/www.provem.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.provem.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.provem.ca\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.provem.ca\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/logo.svg\",\"width\":240,\"height\":55,\"caption\":\"Provem\"},\"image\":{\"@id\":\"https:\\\/\\\/www.provem.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.provem.ca\\\/#\\\/schema\\\/person\\\/61bc22381a98ee7dc1d4468e7cae5e01\",\"name\":\"adminProvem_beta\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1a6e0fb6c1a49d171768af4a202541a4c45b21eb340d80720ea79b09aa7f7a38?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1a6e0fb6c1a49d171768af4a202541a4c45b21eb340d80720ea79b09aa7f7a38?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1a6e0fb6c1a49d171768af4a202541a4c45b21eb340d80720ea79b09aa7f7a38?s=96&d=mm&r=g\",\"caption\":\"adminProvem_beta\"},\"sameAs\":[\"https:\\\/\\\/www.provem.ca\"],\"url\":\"https:\\\/\\\/www.provem.ca\\\/fr\\\/author\\\/adminprovem_beta\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trajectoires th\u00e9rapeutiques en cancers urologiques - Provem","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/","og_locale":"fr_FR","og_type":"article","og_title":"Trajectoires th\u00e9rapeutiques en cancers urologiques - Provem","og_description":"\u00c9valuation longitudinale du paysage th\u00e9rapeutique, de la toxicit\u00e9 et du profilage mol\u00e9culaire des cancers urologiques : une d\u00e9cennie de donn\u00e9es probantes en vie r\u00e9elle Chercheuse principale : Dre Alice DragomirInstitution : McGill University Health Centre (MUHC)Sponsor : PROVEM Contexte scientifique Les cancers urologiques, notamment les cancers de la prostate, de la vessie et du rein, [&hellip;]","og_url":"https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/","og_site_name":"Provem","article_published_time":"2026-03-25T17:35:08+00:00","article_modified_time":"2026-04-01T10:34:26+00:00","og_image":[{"width":1697,"height":1080,"url":"https:\/\/www.provem.ca\/wp-content\/uploads\/2026\/03\/doctor-and-patient-sitting-and-talking-at-medical-2026-03-16-23-01-30-utc.webp","type":"image\/webp"}],"author":"adminProvem_beta","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"adminProvem_beta","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/#article","isPartOf":{"@id":"https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/"},"author":{"name":"adminProvem_beta","@id":"https:\/\/www.provem.ca\/#\/schema\/person\/61bc22381a98ee7dc1d4468e7cae5e01"},"headline":"Trajectoires th\u00e9rapeutiques en cancers urologiques","datePublished":"2026-03-25T17:35:08+00:00","dateModified":"2026-04-01T10:34:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/"},"wordCount":702,"commentCount":0,"publisher":{"@id":"https:\/\/www.provem.ca\/#organization"},"image":{"@id":"https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/#primaryimage"},"thumbnailUrl":"https:\/\/www.provem.ca\/wp-content\/uploads\/2026\/03\/doctor-and-patient-sitting-and-talking-at-medical-2026-03-16-23-01-30-utc.webp","inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/","url":"https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/","name":"Trajectoires th\u00e9rapeutiques en cancers urologiques - Provem","isPartOf":{"@id":"https:\/\/www.provem.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/#primaryimage"},"image":{"@id":"https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/#primaryimage"},"thumbnailUrl":"https:\/\/www.provem.ca\/wp-content\/uploads\/2026\/03\/doctor-and-patient-sitting-and-talking-at-medical-2026-03-16-23-01-30-utc.webp","datePublished":"2026-03-25T17:35:08+00:00","dateModified":"2026-04-01T10:34:26+00:00","breadcrumb":{"@id":"https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/#primaryimage","url":"https:\/\/www.provem.ca\/wp-content\/uploads\/2026\/03\/doctor-and-patient-sitting-and-talking-at-medical-2026-03-16-23-01-30-utc.webp","contentUrl":"https:\/\/www.provem.ca\/wp-content\/uploads\/2026\/03\/doctor-and-patient-sitting-and-talking-at-medical-2026-03-16-23-01-30-utc.webp","width":1697,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.provem.ca\/fr\/trajectoires-therapeutiques-en-cancers-urologiques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.provem.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Trajectoires th\u00e9rapeutiques en cancers urologiques"}]},{"@type":"WebSite","@id":"https:\/\/www.provem.ca\/#website","url":"https:\/\/www.provem.ca\/","name":"Provem","description":"Provem website","publisher":{"@id":"https:\/\/www.provem.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.provem.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.provem.ca\/#organization","name":"Provem","url":"https:\/\/www.provem.ca\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.provem.ca\/#\/schema\/logo\/image\/","url":"https:\/\/www.provem.ca\/wp-content\/uploads\/2026\/01\/logo.svg","contentUrl":"https:\/\/www.provem.ca\/wp-content\/uploads\/2026\/01\/logo.svg","width":240,"height":55,"caption":"Provem"},"image":{"@id":"https:\/\/www.provem.ca\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.provem.ca\/#\/schema\/person\/61bc22381a98ee7dc1d4468e7cae5e01","name":"adminProvem_beta","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/1a6e0fb6c1a49d171768af4a202541a4c45b21eb340d80720ea79b09aa7f7a38?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1a6e0fb6c1a49d171768af4a202541a4c45b21eb340d80720ea79b09aa7f7a38?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1a6e0fb6c1a49d171768af4a202541a4c45b21eb340d80720ea79b09aa7f7a38?s=96&d=mm&r=g","caption":"adminProvem_beta"},"sameAs":["https:\/\/www.provem.ca"],"url":"https:\/\/www.provem.ca\/fr\/author\/adminprovem_beta\/"}]}},"_links":{"self":[{"href":"https:\/\/www.provem.ca\/fr\/wp-json\/wp\/v2\/posts\/1777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.provem.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.provem.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.provem.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.provem.ca\/fr\/wp-json\/wp\/v2\/comments?post=1777"}],"version-history":[{"count":9,"href":"https:\/\/www.provem.ca\/fr\/wp-json\/wp\/v2\/posts\/1777\/revisions"}],"predecessor-version":[{"id":1926,"href":"https:\/\/www.provem.ca\/fr\/wp-json\/wp\/v2\/posts\/1777\/revisions\/1926"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.provem.ca\/fr\/wp-json\/wp\/v2\/media\/1776"}],"wp:attachment":[{"href":"https:\/\/www.provem.ca\/fr\/wp-json\/wp\/v2\/media?parent=1777"}],"wp:term":[{"taxonomy":"type-post","embeddable":true,"href":"https:\/\/www.provem.ca\/fr\/wp-json\/wp\/v2\/type-post?post=1777"},{"taxonomy":"communication-type","embeddable":true,"href":"https:\/\/www.provem.ca\/fr\/wp-json\/wp\/v2\/communication-type?post=1777"},{"taxonomy":"data-type","embeddable":true,"href":"https:\/\/www.provem.ca\/fr\/wp-json\/wp\/v2\/data-type?post=1777"},{"taxonomy":"usage","embeddable":true,"href":"https:\/\/www.provem.ca\/fr\/wp-json\/wp\/v2\/usage?post=1777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}